Based on the recent price action and technical indicators, DHR stock shows a bullish momentum with the price rising from $230 to $253 over the past month. The stock is currently trading above its key moving averages with positive MACD divergence, suggesting further upside potential.

The stock appears to be a buy at current levels with strong technical support around $248-250 range.

What is price prediction 2025 for DHR Stock?

Based on the provided data and market analysis, here is the price prediction for Danaher (DHR) stock in 2025:

DHR is projected to reach $269-275 by end of 2025, representing a ~30% upside from current levels around $209.60, driven by three key factors:

Recovery in Bioprocessing Business

Analysts expect DHR's high-margin bioprocessing segment to see significant improvement in H2 2025
This recovery is anticipated to drive EPS growth to $7.67 in FY2025, up 2.5% year-over-year

Strong Analyst Support

24 analysts maintain overwhelmingly bullish stance with 17 "Strong Buy" ratings
Mean price target of $269.55 indicates 32.4% upside potential
Street-high target of $310 suggests over 50% potential gains

Strategic Growth Initiatives

Recent FDA Breakthrough Designation for Alzheimer's diagnostic test opens up $9B market opportunity
Collaboration with Fujirebio strengthens competitive positioning
Focus on high-margin segments expected to boost profitability

What is surpport and resistant level for DHR Stock?

The S1 support level for DHR Stock is $199.14 ,The R1 resistant level for DHR Stock is $212.01.

What is the current price of DHR Stock?

As of the end of day on 2025-02-26, the price of DHR Stock was $210.29.

What is the target price of DHR Stock?

The target price for DHR Stock according to analyst rating is 263.87, with the highest price target at 300.00 and the lowest at 240.00. Analysts have a Moderate Buy rating on DHR Stock overall.

What is the market cap of Danaher Corp?

The market cap of DHR is $150.4B.

Is Danaher Corp (DHR) overvalued?

Based on the provided data and recent market analysis, here are 5 key points about DHR's valuation:

DHR is currently trading at $209.60, showing significant undervaluation compared to its historical multiples and peer group.

The stock's technical indicators suggest oversold conditions with an RSI of 39.75 and trading below all major moving averages, particularly the 200-day SMA at $250.51.

Recent Q4 earnings missed estimates marginally, causing a 9.7% price drop, but this reaction appears overdone given the company's strong market position in life sciences and diagnostics.

The current P/E of 40.93x is elevated compared to 2022 levels, but justified by the expected recovery in bioprocessing and 10% projected earnings growth in 2025.

Wall Street maintains a "Strong Buy" consensus with a mean price target of $269.55, representing over 32% upside potential from current levels.

What is Danaher Corp (DHR)'s business?

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

What is price prediction 2030 for DHR Stock?

Based on the provided data and analysis, here's a projection for Danaher (DHR) stock price in 2030:

DHR stock is projected to reach $375-400 by 2030, driven by its strong positioning in life sciences and diagnostics markets. The company's breakthrough in the $9 billion Alzheimer's diagnostics market and strategic focus on high-margin bioprocessing within life sciences sector will be key growth catalysts. Currently trading at $209.6, DHR has significant upside potential supported by 24 analysts maintaining a "Strong Buy" rating with a mean price target of $269.55.